Haldol Decanoas

Haldol Decanoas

haloperidol

Manufacturer:

Johnson & Johnson
Concise Prescribing Info
Contents
Haloperidol decanoate
Indications/Uses
Maintenance treatment of chronic schizophrenia & other psychoses.
Dosage/Direction for Use
Initially 25-75 mg daily. Max: 100 mg daily. The dose may gradually be increased by 50 mg until an optimal therapeutic effect is obtained. Elderly & debilitated patient 12.5-25 mg every 4 wk.
Contraindications
Hypersensitivity. Comatose state, CNS depression, Parkinson's disease, lesion of the basal ganglia.
Special Precautions
Not for IV administration. Patients w/ QT-prolonging conditions (eg, QT syndrome, hypokalaemia, electrolyte imbalance, drugs known to prolong QT, CV diseases, family history of QT prolongation); risk factors for stroke; epilepsy & conditions predisposing to convulsions; hyperthyroidism, hyperprolactinaemia; venous thromboembolism. Neuroleptic malignant syndrome; tardive dyskinesia; extrapyramidal symptoms. Should not be used alone where depression is predominant. May impair ability to drive or operate machinery. Liver disease. Pregnancy & lactation. Elderly.
Adverse Reactions
Extrapyramidal disorder, tremor, parkinsonism, somnolence, masked facies, akathisia, sedation, akinesia, dyskinesia, hypertonia, dystonia, cogwheel rigidity; dry mouth, constipation, salivary hypersecretion; muscle rigidity; sexual dysfunction; inj site reaction; increased wt; blurred vision, visual disturbances, oculogyric crisis; tachycardia. Depression, insomnia.
Drug Interactions
Drugs known to prolong QT interval or cause electrolyte imbalance. Mild to moderate increased conc w/ substrates or inhibitors of CYP3A4 or CYP2D6 isozymes eg, itraconazole, nefazodone, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine & promethazine. Increased QTc in combination w/ ketoconazole & paroxetine. Reduced plasma levels w/ prolonged treatment w/ enzyme-inducing drugs eg, carbamazepine, phenobarb, rifampicin. Increased CNS depression w/ other CNS-depressant drugs including alcohol, hypnotics, sedatives or analgesics. Enhanced CNS effect w/ methyldopa. May antagonize the action of adrenaline & other sympathomimetic agents & reverse the BP-lowering effects of adrenergic-blocking agents eg, guanethidine. May impair the antiparkinsonian effects of levodopa. Increased plasma levels of TCAs. Concomitant use w/ lithium. May antagonize effect of phenindione.
MIMS Class
ATC Classification
N05AD01 - haloperidol ; Belongs to the class of butyrophenone derivatives antipsychotics.
Presentation/Packing
Form
Haldol Decanoas inj 50 mg/mL
Packing/Price
1 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in